Selected research
Industry Research
Overactive Bladder (OAB) Therapeutics Industry Research Report 2026
Market perspective
The global Overactive Bladder (OAB) Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Overactive Bladder (OAB) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Overactive Bladder (OAB) Therapeutics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Overactive Bladder (OAB) Therapeutics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Overactive Bladder (OAB) Therapeutics include Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Ion Channel Innovations, Kwang Dong Pharmaceutical, ONO Pharmaceutical, Tengion, GlaxoSmithKline and Ferring, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Overactive Bladder (OAB) Therapeutics market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Overactive Bladder (OAB) Therapeutics Market by Company
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Ion Channel Innovations
Kwang Dong Pharmaceutical
ONO Pharmaceutical
Tengion
GlaxoSmithKline
Ferring
Pfizer
Lanzhou Institute of Biological Products
Merck
Sanofi
Teva Pharmaceutical Industries
Overactive Bladder (OAB) Therapeutics Segment by Type
Anticholinergic Agents
Beta-3 Adrenoreceptor Agonists
Overactive Bladder (OAB) Therapeutics Segment by Application
Hosptial
Clinci
Other
Overactive Bladder (OAB) Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Overactive Bladder (OAB) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Overactive Bladder (OAB) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Overactive Bladder (OAB) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Overactive Bladder (OAB) Therapeutics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Overactive Bladder (OAB) Therapeutics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Overactive Bladder (OAB) Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anticholinergic Agents
- Beta-3 Adrenoreceptor Agonists
Applications
- Hosptial
- Clinci
- Other
Companies covered
- Allergan
- Astellas Pharma
- Hisamitsu Pharmaceutical
- Ion Channel Innovations
- Kwang Dong Pharmaceutical
- ONO Pharmaceutical
- Tengion
- GlaxoSmithKline
- Ferring
- Pfizer
- Lanzhou Institute of Biological Products
- Merck
- Sanofi
- Teva Pharmaceutical Industries
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Overactive Bladder (OAB) Therapeutics Market Size (2021-2032)
- 2.2.2 Global Overactive Bladder (OAB) Therapeutics Sales (2021-2032)
- 2.2.3 Global Overactive Bladder (OAB) Therapeutics Market Average Price (2021-2032)
- 2.3 Overactive Bladder (OAB) Therapeutics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Anticholinergic Agents
- 2.3.3 Beta-3 Adrenoreceptor Agonists
- 2.4 Overactive Bladder (OAB) Therapeutics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hosptial
- 2.4.3 Clinci
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Overactive Bladder (OAB) Therapeutics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Overactive Bladder (OAB) Therapeutics Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Overactive Bladder (OAB) Therapeutics Revenue of Manufacturers (2021-2026)
- 3.4 Global Overactive Bladder (OAB) Therapeutics Average Price by Manufacturers (2021-2026)
- 3.5 Global Overactive Bladder (OAB) Therapeutics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Overactive Bladder (OAB) Therapeutics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Overactive Bladder (OAB) Therapeutics, Product Type & Application
- 3.8 Global Manufacturers of Overactive Bladder (OAB) Therapeutics, Established Date
- 3.9 Global Overactive Bladder (OAB) Therapeutics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Allergan
- 4.1.1 Allergan Company Information
- 4.1.2 Allergan Business Overview
- 4.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.1.5 Allergan Recent Developments
- 4.2 Astellas Pharma
- 4.2.1 Astellas Pharma Company Information
- 4.2.2 Astellas Pharma Business Overview
- 4.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.2.5 Astellas Pharma Recent Developments
- 4.3 Hisamitsu Pharmaceutical
- 4.3.1 Hisamitsu Pharmaceutical Company Information
- 4.3.2 Hisamitsu Pharmaceutical Business Overview
- 4.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.3.5 Hisamitsu Pharmaceutical Recent Developments
- 4.4 Ion Channel Innovations
- 4.4.1 Ion Channel Innovations Company Information
- 4.4.2 Ion Channel Innovations Business Overview
- 4.4.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.4.5 Ion Channel Innovations Recent Developments
- 4.5 Kwang Dong Pharmaceutical
- 4.5.1 Kwang Dong Pharmaceutical Company Information
- 4.5.2 Kwang Dong Pharmaceutical Business Overview
- 4.5.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.5.5 Kwang Dong Pharmaceutical Recent Developments
- 4.6 ONO Pharmaceutical
- 4.6.1 ONO Pharmaceutical Company Information
- 4.6.2 ONO Pharmaceutical Business Overview
- 4.6.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.6.5 ONO Pharmaceutical Recent Developments
- 4.7 Tengion
- 4.7.1 Tengion Company Information
- 4.7.2 Tengion Business Overview
- 4.7.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.7.5 Tengion Recent Developments
- 4.8 GlaxoSmithKline
- 4.8.1 GlaxoSmithKline Company Information
- 4.8.2 GlaxoSmithKline Business Overview
- 4.8.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.8.5 GlaxoSmithKline Recent Developments
- 4.9 Ferring
- 4.9.1 Ferring Company Information
- 4.9.2 Ferring Business Overview
- 4.9.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.9.5 Ferring Recent Developments
- 4.10 Pfizer
- 4.10.1 Pfizer Company Information
- 4.10.2 Pfizer Business Overview
- 4.10.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.10.5 Pfizer Recent Developments
- 4.11 Lanzhou Institute of Biological Products
- 4.11.1 Lanzhou Institute of Biological Products Company Information
- 4.11.2 Lanzhou Institute of Biological Products Business Overview
- 4.11.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.11.5 Lanzhou Institute of Biological Products Recent Developments
- 4.12 Merck
- 4.12.1 Merck Company Information
- 4.12.2 Merck Business Overview
- 4.12.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Merck Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.12.5 Merck Recent Developments
- 4.13 Sanofi
- 4.13.1 Sanofi Company Information
- 4.13.2 Sanofi Business Overview
- 4.13.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.13.5 Sanofi Recent Developments
- 4.14 Teva Pharmaceutical Industries
- 4.14.1 Teva Pharmaceutical Industries Company Information
- 4.14.2 Teva Pharmaceutical Industries Business Overview
- 4.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio
- 4.14.5 Teva Pharmaceutical Industries Recent Developments
5 Global Overactive Bladder (OAB) Therapeutics Market Scenario by Region
- 5.1 Global Overactive Bladder (OAB) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2021-2032
- 5.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2021-2026
- 5.2.2 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2027-2032
- 5.3 Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2021-2032
- 5.3.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2021-2026
- 5.3.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2027-2032
- 5.4 North America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
- 5.4.1 North America Overactive Bladder (OAB) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2032)
- 5.4.3 North America Overactive Bladder (OAB) Therapeutics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
- 5.5.1 Europe Overactive Bladder (OAB) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2032)
- 5.5.3 Europe Overactive Bladder (OAB) Therapeutics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
- 5.7.1 South America Overactive Bladder (OAB) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2032)
- 5.7.3 South America Overactive Bladder (OAB) Therapeutics Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2032)
- 6.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2021-2032)
- 6.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2032)
- 6.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2021-2032)
- 6.3 Global Overactive Bladder (OAB) Therapeutics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2032)
- 7.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2021-2032)
- 7.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2032)
- 7.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2021-2032)
- 7.3 Global Overactive Bladder (OAB) Therapeutics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Overactive Bladder (OAB) Therapeutics Value Chain Analysis
- 8.1.1 Overactive Bladder (OAB) Therapeutics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Overactive Bladder (OAB) Therapeutics Production Mode & Process
- 8.2 Overactive Bladder (OAB) Therapeutics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Overactive Bladder (OAB) Therapeutics Distributors
- 8.2.3 Overactive Bladder (OAB) Therapeutics Customers
9 Global Overactive Bladder (OAB) Therapeutics Analyzing Market Dynamics
- 9.1 Overactive Bladder (OAB) Therapeutics Industry Trends
- 9.2 Overactive Bladder (OAB) Therapeutics Industry Drivers
- 9.3 Overactive Bladder (OAB) Therapeutics Industry Opportunities and Challenges
- 9.4 Overactive Bladder (OAB) Therapeutics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst